Will a cheaper diabetes pill match the original?

NCT ID NCT07763951

Completed Knowledge-focused Sponsor: ADIUM Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial checks whether a generic extended-release tablet containing sitagliptin and metformin works the same as the brand-name Janumet XR. Healthy adults aged 18 to 55 take a single dose of each version on separate occasions, and researchers compare how much of the drugs reach the bloodstream. The goal is to confirm the generic is bioequivalent, meaning it delivers the same amount of medication, so it could be used as a lower-cost alternative.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sitagliptin/metformin extended-release tablets
What this could lead to: If the generic tablet proves equivalent, it could offer a more affordable option for people managing type 2 diabetes.
What could go wrong: This is a small, early-stage study in healthy volunteers, not patients. Results may not reflect real-world use, and the generic could still fail to match the brand version.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOEQUIVALANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOEQUIVALANCE

Contacts and locations

Locations

Axis Clinicals Latina, S.A. de C.V.

Mexico City, Mexico City, 07870, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.